Valeritas
Bridgewater
About Valeritas
Valeritas is a medical technology company committed to developing and commercializing innovative drug delivery solutions that contribute to clinical and humanistic outcomes for patients, with an initial focus on the treatment of diabetes. Valeritas' medical technologies portfolio is headlined by the h-Patch technology. The first use of the h-Patch technology will be the V-Go disposable insulin delivery device for continuous delivery both at a preset basal rate and for on-demand bolus dosing at mealtimes. The V-Go is a simple-to-use, once-daily, disposable insulin delivery device that provides a preset basal rate and on-demand bolus dosing for mealtime coverage via a mealtime insulin. The V-Go will enable the millions suffering from Type 2 diabetes to conveniently and discreetly deliver insulin throughout the day bolus dose on-demand around mealtimes. The h-Patch technology is also being developed to serve as a launching platform for applications across a wide spectrum of medical needs.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $355.0M
- Funding stage: M&A
- Last round: Series Unknown (May 2016)
- Ticker: nasdaq:VLRX
- Website: valeritas.com
- Phone: 908-927-9920
Industries & Categories
Biotechnology, Diabetes, Health Care, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/valeritas-194218 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.